- Home
- MTRX vs ESPR Comparison
MTRX vs ESPR Comparison
Compare MTRX & ESPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MTRX
- ESPR
- Stock Information
- Founded
- MTRX 1984
- ESPR 2008
- Country
- MTRX United States
- ESPR United States
- Employees
- MTRX N/A
- ESPR N/A
- Industry
- MTRX Engineering & Construction
- ESPR Biotechnology: Pharmaceutical Preparations
- Sector
- MTRX Consumer Discretionary
- ESPR Health Care
- Exchange
- MTRX Nasdaq
- ESPR Nasdaq
- Market Cap
- MTRX 293.9M
- ESPR 319.2M
- IPO Year
- MTRX 1990
- ESPR 2013
- Fundamental
- Price
- MTRX $12.52
- ESPR $2.12
- Analyst Decision
- MTRX Strong Buy
- ESPR Buy
- Analyst Count
- MTRX 1
- ESPR 4
- Target Price
- MTRX $18.00
- ESPR $8.17
- AVG Volume (30 Days)
- MTRX 124.4K
- ESPR 4.8M
- Earning Date
- MTRX 11-06-2024
- ESPR 11-07-2024
- Dividend Yield
- MTRX N/A
- ESPR N/A
- EPS Growth
- MTRX N/A
- ESPR N/A
- EPS
- MTRX N/A
- ESPR N/A
- Revenue
- MTRX $696,133,000.00
- ESPR $295,451,000.00
- Revenue This Year
- MTRX $28.10
- ESPR $198.22
- Revenue Next Year
- MTRX $13.85
- ESPR $25.83
- P/E Ratio
- MTRX N/A
- ESPR N/A
- Revenue Growth
- MTRX N/A
- ESPR 187.12
- 52 Week Low
- MTRX $8.61
- ESPR $1.08
- 52 Week High
- MTRX $13.90
- ESPR $3.40
- Technical
- Relative Strength Index (RSI)
- MTRX 58.74
- ESPR 50.12
- Support Level
- MTRX $12.65
- ESPR $1.87
- Resistance Level
- MTRX $13.24
- ESPR $2.60
- Average True Range (ATR)
- MTRX 0.52
- ESPR 0.17
- MACD
- MTRX 0.08
- ESPR -0.01
- Stochastic Oscillator
- MTRX 64.63
- ESPR 34.25
About MTRX Matrix Service Company
Matrix Service Co is an engineering and construction provider for large industrial projects, primarily in the oil and gas, power, petrochemical, industrial, mining, and minerals markets. It offers engineering, fabrication, construction, and maintenance services, operating across three segments namely Utility and Power Infrastructure; Process and Industrial Facilities and Storage and Terminal Solutions.
About ESPR Esperion Therapeutics Inc.
Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The Company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.